TY - JOUR
T1 - Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma
T2 - A prospective, multicenter, phase II study
AU - Offidani, Massimo
AU - Corvatta, Laura
AU - Marconi, Monica
AU - Visani, Giuseppe
AU - Alesiani, Francesco
AU - Brunori, Marino
AU - Galieni, Piero
AU - Catarini, Massimo
AU - Burattini, Maurizio
AU - Centurioni, Riccardo
AU - Rupoli, Serena
AU - Scortechini, Anna Rita
AU - Giuliodori, Luciano
AU - Candela, Marco
AU - Capelli, Debora
AU - Montanari, Mauro
AU - Olivieri, Attilio
AU - Piersantelli, Maria Novella
AU - Leoni, Pietro
PY - 2006/1
Y1 - 2006/1
N2 - The aim of this prospective, multicenter, phase II study was to investigate the combination of pegylated liposomal doxorubicin (Caelyx®) 40 mg/m 2 on day 1 every 28 days, dexamethasone 40 mg p.o. on days 1-4 and 9-12 and thalidomide 100 mg daily in 50 patients with advanced multiple myeloma. Twenty-six percent of patients achieved a complete reponse, 6% a near complete response, 6% a very good partial response, 38% a partial response, 16% a minor response and 8% progressed, for an overall response rate of 92%. The median event-free survival was 17 months and the median overall survival was not reached. Grade 3 non-hematologic toxicity occurred in 12% of patients, thromboembolic disease in 12% and severe infection in 16%. The combination of pegylated liposomal doxorubicin, dexamethasone an thalidomide is safe and very effective in advanced multiple myeloma.
AB - The aim of this prospective, multicenter, phase II study was to investigate the combination of pegylated liposomal doxorubicin (Caelyx®) 40 mg/m 2 on day 1 every 28 days, dexamethasone 40 mg p.o. on days 1-4 and 9-12 and thalidomide 100 mg daily in 50 patients with advanced multiple myeloma. Twenty-six percent of patients achieved a complete reponse, 6% a near complete response, 6% a very good partial response, 38% a partial response, 16% a minor response and 8% progressed, for an overall response rate of 92%. The median event-free survival was 17 months and the median overall survival was not reached. Grade 3 non-hematologic toxicity occurred in 12% of patients, thromboembolic disease in 12% and severe infection in 16%. The combination of pegylated liposomal doxorubicin, dexamethasone an thalidomide is safe and very effective in advanced multiple myeloma.
UR - http://www.scopus.com/inward/record.url?scp=32544447241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=32544447241&partnerID=8YFLogxK
M3 - Article
C2 - 16434383
AN - SCOPUS:32544447241
SN - 0390-6078
VL - 91
SP - 133
EP - 136
JO - Haematologica
JF - Haematologica
IS - 1
ER -